Breast cancer recurrence · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance showed no clear difference in breast cancer recurrence compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review
Breast Cancer‐related Death · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance showed no clear difference in breast cancer‐related death compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review
Proportion of participants with re‐epithelialization and complete healing with or without scar formation at 4 to 8 weeks Assessed by slit‐lamp biomicroscopy · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
no estimate extracted
15 participants
Very low
Proportion of participants with BCVA of 20/100 or better at 4 to 8 weeks Assessed using a logMAR chart · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
no estimate extracted
12 participants
Very low
Mean change from baseline in BCVA at 4 to 8 weeks Assessed using a logMAR chart · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Proportion of participants with a reduction in corneal infiltrate at 4 to 8 weeks Assessed by outcome assessors · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Proportion of participants with reduction in intraocular inflammation at 4 to 8 weeks Assessed by corneal keratic precipitates, anterior chamber cellular reaction, or other appropriate measure · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Proportion of participants with treatment failure at 4 to 8 weeks Assessed by outcome assessors · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
Proportion of participants with adverse events at 4 to 8 weeks Assessed by outcome assessors · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
Complications
Postoperative parenteral nutrition may leads to higher complications compared with oral nutrition alone (low certainty).
1 finding from 1 review
Length of hospital stay
1 finding from 1 review
All‐cause mortality
It is very uncertain whether postoperative parenteral nutrition changes mortality compared with oral nutrition alone (very low certainty).
1 finding from 1 review
The incidence and severity of toxicities: leukopenia (WHO grade 3 to 4) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment showed no clear difference in the incidence and severity of toxicities: leukopenia (WHO grade 3 to… compared with conventional medicine alone (low certainty).
1 finding from 1 review
QoL · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment may leads to higher qoL (EORTC QLQ‐c30) compared with conventional medicine alone (low certainty).
1 finding from 1 review
Patient‐reported symptom: nausea/vomiting (WHO grade 3 to 4) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment may leads to lower patient‐reported symptom: nausea/vomiting (WHO grade 3 to 4) compared with conventional medicine alone (low certainty).
1 finding from 1 review
Diarrhoea · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment showed no clear difference in patient‐reported symptom: diarrhoea compared with conventional medicine alone (low certainty).
1 finding from 1 review
Time to recurrence
Single‐dose, preoperative MMC‐EMDA probably leads to lower time to recurrence compared with TURBT alone (moderate certainty).
1 finding from 1 review
Time to progression
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes time to progression compared with TURBT alone (very low certainty).
1 finding from 1 review
Serious adverse events
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with TURBT alone (very low certainty).
1 finding from 1 review
Disease‐specific survival
Single‐dose, preoperative MMC‐EMDA showed no clear difference in disease‐specific survival compared with TURBT alone (moderate certainty).
1 finding from 1 review